TCGA-66-2753-01A-01R-0980-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 69
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.600
- G2M_CHECKPOINT+0.510
- UNFOLDED_PROTEIN_RESPONSE+0.510
- MYC_TARGETS_V1+0.500
- E2F_TARGETS+0.470
- MTORC1_SIGNALING+0.440
- PROTEIN_SECRETION+0.420
- ANDROGEN_RESPONSE+0.400
- ANGIOGENESIS+0.350
- CHOLESTEROL_HOMEOSTASIS+0.330
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.380
- PANCREAS_BETA_CELLS-0.310
- INTERFERON_GAMMA_RESPONSE-0.290
- KRAS_SIGNALING_DN-0.280
- MYOGENESIS-0.280
- ALLOGRAFT_REJECTION-0.260
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.230
- NOTCH_SIGNALING-0.220
- APICAL_SURFACE-0.180
- COAGULATION-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-85-8351-01A-11R-2296-07 | — | cohortSQ1 | 0.860 |
| 2 | ERR2598051 | fetal | fetal | 0.843 |
| 3 | BS_9XVACXP0 | high-grade glioma | — | 0.836 |
| 4 | ERR2598169 | fetal | fetal | 0.835 |
| 5 | SRR4195653 | — | — | 0.835 |
| 6 | MDT-AP-3285 | Med | Medulloblastoma | 0.835 |
| 7 | TCGA-56-7222-01A-11R-2045-07 | — | cohortSQ1 | 0.833 |
| 8 | TCGA-H7-8502-01A-11R-2403-07 | — | — | 0.829 |
| 9 | 07D10802-F79E-495E-B842-895C444CA439 | — | — | 0.822 |
| 10 | SRR12696801 | — | — | 0.821 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.510 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.510 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.440 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.420 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.350 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.330 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.290 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.290 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.250 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.240 | Inavolisib | — uncovered |
| HYPOXIA | 0.220 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |